Otitopic has announced that a Phase 1 trial of its Asprihale dry powder aspirin found that the inhaled formulation demonstrated antithrombotic effects at 2 minutes post dose compared to 30 minutes post dose for a 162 mg chewable aspirin tablet. Both the inhaled and chewable aspirin maintained maximum antithrombotic effects at 24 hours post dose.
In February 2019, Otitopic announced that it had received several US patents covering Asprihale, which the company is developing for the treatment of suspected acute myocardial infarction. The company has also said that it plans to develop the inhaled aspirin for the treatment of lung cancer.
Otitopic CEO Kambiz Yadidi commented, “We are highly encouraged by the level of safety, tolerability, and data observed with the dry powder inhalation of aspirin. We are proud to own the intellectual property of such a revolutionizing lifesaving product.”
The company said that it intends to conduct a pivotal clinical trial of Asprihale for the treatment of myocardial infarction in 2020.
Read the Otitopic press release.
